Skip to main content
Clinical Trials/NCT05707845
NCT05707845
Completed
Not Applicable

Effect of Weight Reduction and Aerobic Exercise on Premenstrual Syndrome Symptoms in Obese Females

Cairo University1 site in 1 country40 target enrollmentMay 1, 2023

Overview

Phase
Not Applicable
Intervention
Medical treatment.
Conditions
Premenstrual Syndrome
Sponsor
Cairo University
Enrollment
40
Locations
1
Primary Endpoint
body weight
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study will be investigation of the effect of weight reduction and aerobic exercises on premenstrual syndrome symptoms in obese females.

Detailed Description

both groups (A\&B) will take their medical treatment in the form of (NSAIDs) and the study group B will under go a siet plan which will fits the participants. Diet plan extends for 12 weeks in the form of caloric restriction program and each woman in group B will perform aerobic exercise program, in the form of treadmill 3 times/week for 8 weeks for 12 weeks. Each session will take about 30 minutes as the following: 5 minutes warming up exercises by walking on the treadmill by low speed, 20 minutes walking at moderate intensity (70% of the maximal heart rate) and 5 minutes are cooling down by walking on the treadmill by low speed as in warming up.

Registry
clinicaltrials.gov
Start Date
May 1, 2023
End Date
December 1, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yara Mostafa Soliman Mahmoud Abdlbary

M.SC physical therapy

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Age will range between 20- 30 years old.
  • only females will participate in the study.
  • All patients who will be enrolled to the study will have their informed consent.

Exclusion Criteria

  • Diabetes mellitus.
  • Individuals with cardiopulmonary conditions.
  • Individuals with any pelvic disease.
  • Individuals undergoing radiation therapy or chemotherapy.
  • Hepatic or pancreatic diseases.

Arms & Interventions

control group (A)

Group A: (control group): 20 participants Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs)

Intervention: Medical treatment.

study group (B)

Group B: (Study group): 20 participants * Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs). * Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks.

Intervention: Medical treatment.

study group (B)

Group B: (Study group): 20 participants * Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs). * Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks.

Intervention: weight reduction

study group (B)

Group B: (Study group): 20 participants * Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs). * Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks.

Intervention: exercise

Outcomes

Primary Outcomes

body weight

Time Frame: 12 weeks

Weight and height measurement will be measured while the woman is wearing a thin layer of clothes to calculate the BMI according to the following equation for both groups (A\&B): BMI = weight/height2 (kg/m2).

Waist and hip circumference measurements

Time Frame: 12 weeks

Waist circumference was measured at the narrowest point between xipho-sternum and the iliac crest at the end of a gentle expiration; hip circumference was measured at the maximum circumference at the level of femoral trochanter. Then, waist/hip ratio was calculated by dividing waist circumference on hip circumference. All measurements were taken for all patients in both groups (A\&B), while the patient was in the standing position, before starting and after the end of the treatment course.

Progesterone levels in blood

Time Frame: 12 weeks

progesterone level will be checked six to eight days after ovulation start (about day 21st of a 28-day cycle)

Premenstrual syndrome score

Time Frame: 12 weeks

The premenstrual syndrome scale comprised 40 questions with three sub-scales (Physiological, Psychological and Behavioural symptoms). This 5-point Likert- type scale consisting of 40 items. The measurements on the scale are set according to the following scoring system: the response Never was scored as "1", rarely as "2", sometimes as "3", very often as "4" and always as "5" points, the total score obtained from the sub-scales established the "PMSS total score." The scale's lowest score is 40 and highest score is 200. If the scale's total score reached 80 points or above, this indicates the occurrence of PMS. Increases in the scores indicate an increase in PMS severity.

cortisol levels in blood

Time Frame: 12 weeks

All women in both groups (A\&B) will be evaluated before and after the treatment (12 weeks) to show serum cortisol level. A blood sample was taken from each female in both groups (A \& B) before and after the treatment to measure the serum cortisol levels, which could reflect anxiety and pain intensity with decreased cortisol levels indicating decreased pain intensity. The cortisol level was assessed 5 days before the first day of the menstrual cycle preceding the treatment program and 5 days before the first day of the menstrual cycle at the end of treatment program,Blood sample of about 5 cm was drawn from the anticubital vein from all participants by disposable sterile syringe by vein puncture to determine plasma cortisol level. All blood samples were taken at 8-9 am and the norm cortisol level at 9 A.M ranges from 4.3-22.4 ug/dl.

Study Sites (1)

Loading locations...

Similar Trials